Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Safety profile of mycophenolate mofetil: a response

Bone Marrow Transplantation volume 27, page 892 (2001)Cite this article

Drs Basara and Fauser's thoughful and insightful comments1 reinforce what we have documented in our report, namely that mycophenolate mofetil (MMF) can be safely used for the treatment of chronic GVHD with few side-effects occurring in a minority of the patients.2

In our study, adverse gastrointestinal events including diarrhea, nausea and vomiting were the most common clinically relevant side-effects, occurring in 30% (five out of 15) of the patients, whereas severe liver toxicity occurred in one case. Nevertheless, it should be emphasized that MMF was discontinued in only two patients (13%) due to the presence of adverse reactions.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Basara N, Fauser AA . Safety profile of mycophenolate mofetil Bone Marrow Transplant 2000 26: 1362–1363

    Article  CAS  Google Scholar 

  2. Busca A, Saroglia EM, Lanino E et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation Bone Marrow Transplant 2000 25: 1067–1071

    Article  CAS  Google Scholar 

  3. Basara N, Blau WI, Romer E et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients Bone Marrow Transplant 1998 22: 61–65

    Article  CAS  Google Scholar 

  4. Mookerjee B, Altomonte V, Vogelsang G . Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus Bone Marrow Transplant 1999 24: 517–520

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone Marrow Transplant Unit, Ospedale Maggiore San Giovanni Battista, Corso Bramante 88, Turin, 10126, Italy

    A Busca, F Locatelli & M Falda

Authors
  1. A Busca
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Locatelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Falda
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Busca, A., Locatelli, F. & Falda, M. Safety profile of mycophenolate mofetil: a response. Bone Marrow Transplant 27, 892 (2001). https://doi.org/10.1038/sj.bmt.1703018

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703018

This article is cited by

Search

Advanced search

Quick links